RuiTu Bio Completes Over RMB 100 Million Series B2 Financing to Accelerate Commercialization of AI-Powered Clinical Laboratories

VCBeat has learned that Shenzhen Reetoo Biotechnology Co., Ltd. (“Reetoo”) recently announced the successful completion of its Series B2 financing round, exceeding RMB 100 million. This round of financing was led byCAS Investment, a well-known domestic fund as lead investor, and Shenzhen City Investment Control Capital Co., Ltd.Participating in the investment, with Dianshi Capital serving as the exclusive financial advisor. Since its inception, Reetoo has received continuous support from professional investment institutions such as Zhouling Capital, CMB International, and Legend Star. The proceeds from this financing round will be primarily used for the production, commercialization, and R&D iteration of its core products.

Reetoo, founded in 2017 and headquartered in Shenzhen, focuses on the deep integration of artificial intelligence and medical diagnostics. Leveraging its independently developed next-generation DeepCell AI engine, the company has developed four analytical systems: Intelligent Clinical Laboratory, Intelligent Hematology, Intelligent Pathology, and Intelligent Reproductive Medicine. Reetoo is committed to providing customers with cost-effective, high-efficiency AI-powered solutions for cytological testing. Its product matrixCovers multiple testing scenarios, including blood, body fluids, tissues, and sputum, facilitating the standardization and intelligent automation of the entire testing workflow.

As of now, reetoo has obtained 37 Class II registration certificates and over 400 patents; its core productsAchieved full coverage across 32 provinces, with over 1,500 hospital admissions and benchmark hospitals distributed throughout China.

Earlier this year, reetoo launchedNew AI-Powered Automated Workflow for Reproductive Tract Microecology, when paired with the company’s commercially launched RT-F600/RT-F2000A vaginal secretion analyzer, provides an intelligent comprehensive solution for gynecology, achieving fully automated and intelligent testing throughout the entire specimen workflow. It leverages unique optical imaging technology and advanced AIGC (Artificial Intelligence Generated Content) technology to deliver intelligent high-definition imaging.No manual intervention required, with a concordance rate of over 95% compared to manual microscopy.

As the lead organization, reetoo, in collaboration with dozens of large and authoritative medical institutions, drafted and publishedChina's First "Expert Consensus and Guidelines on Gynecological Vaginal Secretion Testing" and "Standardized Guidelines for Clinical Laboratory Testing and Result Reporting of Vaginal Secretions"To provide more accurate and standardized diagnostic and treatment standards for clinical practice, the RT-F600/RT-F2000A Intelligent Vaginal Secretion Analyzer has consecutively won the championship at the “Medical Laboratory Artificial Intelligence and Big Data Development Forum & The First Medical Laboratory Morphology Human-Machine Competition” in both 2021 and 2022.

The company’s fully automated hematology analysis line, comprising the BF8201P/BF8202P automated hematology analyzers, the BD2000 automated slide maker and stainer, the MS2300 microscopic image scanner, and cell morphology analysis software, leverages AI expertise and meticulous engineering to deliver a complete solution for CBC testing, slide preparation, staining, and review in a footprint of less than 1.4 meters. Truly embodying “compactness, speed, precision, and accuracy,” it empowers precision medicine through “high-end intelligent manufacturing.”

Meanwhile, the company is actively expanding its overseas sales. Its products have obtained more than 80 CE certifications, and items such as the intelligent urine analysis system have been sold to over 10 countries and regions, including Europe and the Middle East, providing global customers with intelligent comprehensive solutions.

Reetoo’s management team possesses extensive R&D and commercialization experience in AI+IVD, establishing a closed-loop development strategy encompassing R&D, production, and sales. Dr. Li Qiaoliang and Dr. Qi Suwen previously served together as faculty members in the In Vitro Diagnostics (IVD) Technology Department at Shenzhen University—the first of its kind in China. Having worked together for over a decade, they jointly developed more than ten innovative diagnostic products, including China’s first fully automated chemiluminescence immunoassay analyzer, fully automated CRP analyzer, and fully automated glycated hemoglobin analyzer. The senior sales executives each boast over 15 years of IVD sales experience, with a proven track record of scaling businesses from inception to hundreds of millions in revenue.

Dr. Li Qiaoliang, Founder of ReetooIt stated: “Laboratory medicine has undergone 70 years of automation, achieving assembly-line processing for the majority of testing activities. With the rapid advancement of artificial intelligence (AI), cell morphology analysis, which still heavily relies on manual intervention, is poised for disruption. Looking ahead to the AI era, clinical laboratories will become highly intelligent and automated, enabling unattended operations and serving as hubs for information generation and analysis. Leveraging its AI engine, Reetoo has deployed intelligent automation workflows across multiple scenarios—including blood, body fluids, tissues, and sputum—starting from cell morphology analysis, and will continue to explore the infinite possibilities of AI+IVD.”

Wang Dunshi, Deputy General Manager of CAS Investmentstated: “Over the past few decades, China’s laboratory medicine sector has strived to catch up with advanced international standards, and hospitals across the country have initially achieved widespread availability of testing services. Automation and intelligence will be key to further enhancing the efficiency and accuracy of laboratory testing. The rapid development of artificial intelligence over the past decade has provided Chinese IVD manufacturers with an opportunity to leapfrog their competitors. Reetoo possesses leading AI technologies, robust automation capabilities, and a sales team capable of winning tough battles. We are optimistic about the company’s growth into a distinctive, globally competitive Chinese IVD enterprise.”

Dr. Liu Haijie, Shenzhen City Investment Control Capital Co., Ltd.stated: “In the era of artificial intelligence, clinical laboratories will become highly intelligent and automated, with Reetoo leading the IVD industry toward intelligent transformation. The team possesses extensive R&D and commercialization experience in the AI+IVD sector, demonstrating strong cohesion and high execution efficiency. We are honored to participate in this round of financing and look forward to seeing the company reach new heights through the joint efforts of Dr. Li, Dr. Qi, and the entire team. We are confident in the company’s future development.”

Reetoo is a national high-tech enterprise integrating the R&D, production, and sales of AI-powered in vitro diagnostic (IVD) products. By establishing an AI Medical Laboratory Innovation Center, Reetoo is leading the medical diagnostics industry from automation to intelligence. The company boasts a 14,000 m² modern R&D center and production base, with a sales and service network covering 32 provinces and municipalities across China. It holds over 400 patents, has launched China’s first AI Medical Laboratory Innovation and Entrepreneurship Center, and has been recognized on the Top 100 List of Innovative Medical Devices, the Top 100 Emerging Companies in China’s Medical Device Industry (2023), and the Top 50 Pioneer Enterprises in Biotechnology Innovation in the Guangdong-Hong Kong-Macao Greater Bay Area (4th Edition).

CAS Investment is a professional investment management company under the Chinese Academy of Sciences. CAS Investment has been honored with numerous accolades, including Financing China’s “Top 30 Best Venture Capital Firms in China for 2022” and “Top 10 Private Equity Firms with Best Returns from 2017 to 2022,” Zero2IPO’s “Top 35 Private Equity Firms in China for 2022,” and Preqin’s “Top 10 Fund Managers with the Most Stable Top-Tier Performance in Greater China.” In the healthcare sector, it has invested in leading enterprises across niche industries such as innovative drugs, minimally invasive interventions, precision diagnosis and treatment, and surgical intelligence. Beyond healthcare, CAS Investment focuses on investments in industrial technologies represented by advanced manufacturing, new energy, and aerospace, as well as in integrated circuits, software, and big data, thereby facilitating the rapid growth of portfolio companies.

Shenzhen Investment Holdings Co., Ltd. (SIHC), established in 2004, is a Fortune Global 500 company. As Shenzhen’s largest state-owned capital investment and operation company and the city’s key science and technology financial control platform, SIHC focuses on industrial investment to build three major industrial clusters: science and technology parks, sci-tech industries, and sci-tech finance. With a registered capital of RMB 5 billion, Shenzhen City Investment Control Capital Co., Ltd., a wholly-owned subsidiary of SIHC, serves as the core implementation platform for strategic investment, capital operations, and fund cluster management.